MNC China Lens

Otsuka Pharmaceutical announced that its anti-APRIL monoclonal antibody, sibeprenlimab (brand name: VOYXACT®), has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with primary IgA nephropathy. As the first therapy selectively targeting APRIL (A Proliferation-Inducing Ligand), sibeprenlimab intervenes in disease progression at its source by blocking a key step in the generation of pathogenic IgA.

The development of this sector has three distinct milestones: from 2019 to 2021, it was in an exploratory phase, with only a few small-sample clinical trials conducted in China; from 2022 to 2024, it entered a critical period for regulatory approval, during which multiple companies advanced their efforts simultaneously, yet no product obtained NMPA registration certification; in 2025,H&H Healthcare's K-Clip received approval, marking the official start of the commercialization era and serving as a turning point for the sector's development.

This collaboration aims to discover candidate drugs with clinical differentiation advantages for high-potential therapeutic targets. By applying advanced generative AI models to the early stages of drug development, both teams are poised to comprehensively enhance the quality of candidate molecule design and conduct structural optimization, striving to achieve best-in-class efficacy and ideal safety profiles.

According to reports, PRIMEAI's artificial intelligence modules can achieve gross margins of 70% to 80%, with overall delivery gross margins exceeding 60%. This high-profitability business model precisely aligns with pharmaceutical companies' demands for cost reduction and efficiency improvement. In 2026, the company is projected to achieve revenue exceeding RMB 100 million, with total contract value approaching RMB 160 million, marking the entry of its commercialization into a phase of exponential growth.

Alebund Pharmaceuticals (Jiangsu) Limited, a clinical-stage biotech focused on chronic kidney disease treatments, made its debut on the Hong Kong Stock Exchange June 29, 2026, with its stock jumping more than 95% to HK$44 at press time and valuing the firm at roughly HK$15 billion. The IPO is set to raise HK$1.181 billion, with 34% earmarked for the New Drug Application filing and global Phase 3 multi-center studies of flagship asset AP301, 37% allocated to global Phase 2b trials for AP306 alongside progress on pipeline candidates including AP308 and AP303, and 12% designated for capacity expansion at its Yangzhou manufacturing facility and pre-launch commercial preparations for future approved therapies.

It forms an effective portfolio strategy with Keppra: Keppra, as a broad-spectrum foundational medication, covers a wide patient population with epilepsy and provides stable cash flow; Vimpat, as a next-generation specialized product, targets more segmented treatment scenarios with higher efficacy demands, representing future growth potential. This "cornerstone product + growth product" combination effectively balances current revenue with future opportunities.